Is Mounjaro Discontinued — or Just Hard to Find Right Now?

Step 1, Understand the difference between a shortage and a discontinuation

A medicines discontinuation is a formal regulatory event in which a manufacturer withdraws a product's marketing authorisation or permanently ceases production. That has not happened with Mounjaro. Eli Lilly holds an active MHRA authorisation for tirzepatide across all six UK strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) and continues to supply pharmacies through the licensed UK distribution network.

What has happened is a demand surge. NICE published its recommendation for tirzepatide in December 2024, and NHS England began phased prescribing from June 2025. That influx of new patients, on top of existing private prescriptions, created pressure the supply chain was not immediately sized for. Individual pharmacies, particularly those without dedicated clinical stock arrangements, have found certain strengths temporarily unavailable. That is a stock problem, not a product withdrawal.

The NHS medicines information service and the NHS patient page on tirzepatide remain live precisely because the medicine is still licensed and in active use. If Mounjaro were being discontinued, both the MHRA and Eli Lilly would be required to issue formal communications and manage patient transition, none of that has occurred.

Step 2, Check whether your specific strength is the issue, not the whole range

Shortages rarely affect every strength simultaneously. Higher maintenance doses (10 mg, 12.5 mg and 15 mg) have historically faced tighter availability during peak demand, while starter strengths have sometimes remained accessible. This matters because a blanket internet search for "Mounjaro discontinued" can be triggered by a patient who cannot find 12.5 mg at their usual pharmacy, even though other strengths are in stock elsewhere.

Before assuming the medicine is gone, it is worth asking your prescriber or pharmacist which strengths are currently accessible. They may be able to contact alternative dispensing pharmacies on your behalf. Dose continuity matters clinically, pausing treatment, especially mid-titration, can mean restarting from a lower dose, so this is a conversation to have promptly rather than waiting.

If you are considering switching provider during a shortage, the Mounjaro treatment page explains what a transfer to a new pharmacy typically involves, including the evidence checks a responsible prescriber should complete before continuing your current dose.

Step 3, Stay safe: counterfeit risk is highest when supply is tight

Supply gaps are exactly the moment counterfeit sellers become more visible online. The MHRA has warned publicly and repeatedly about fake weight-loss pens sold through social media and websites that offer tirzepatide without a prescription or clinical assessment. In October 2025, the MHRA raided an illicit manufacturing site in Northampton producing counterfeit tirzepatide pens, you can report any suspect seller directly via the Yellow Card scheme. Fake pens have been found to contain incorrect substances, incorrect doses, and in some cases insulin, which poses life-threatening risk.

The only safe way to obtain Mounjaro is through a GPhC-registered pharmacy dispensing against a valid UK prescription. You can verify any online pharmacy on the GPhC register at pharmacyregulation.org/registers. A seller offering tirzepatide without a clinical assessment, at prices far below the market range, or with "discount codes" attached, is a red flag, not a solution to a shortage.

Understanding the cost picture during a shortage is also useful context; the Mounjaro cost page explains what legitimate private pricing covers and why large price discrepancies between suppliers should prompt caution rather than a quick purchase.

Step 4, What to do right now if your treatment has been disrupted

If you are an existing patient and your current pharmacy cannot fulfil your prescription, contact your prescriber before taking any action. They can advise on whether to pause, continue at a lower dose, or transfer your care. Missing a dose or two is generally manageable clinically, but self-adjusting without guidance risks unnecessary side effects or restarting a titration schedule from scratch.

For anyone who has not yet started treatment and wants to understand the full clinical picture, including how tirzepatide was discovered and developed into the medicine it is today, what the eligibility criteria are, and how a responsible prescriber structures treatment, the broader tirzepatide information page covers that ground clearly. The weight-loss treatment overview also explains how different licensed options compare if a prescriber suggests considering alternatives during a prolonged supply gap.

At nume, every repeat order is clinically reviewed before it is dispensed, and our pharmacy works within the authorised UK supply chain. If you keep a pen in the fridge door as part of your weekly routine, the last thing you want is uncertainty about where next month's supply is coming from, and if you are wondering whether you can take Gaviscon alongside Mounjaro to manage digestive symptoms, that is exactly the kind of practical question our clinical team is here to answer. That certainty is one of the things a properly registered, clinician-led pharmacy is designed to provide. If you want to explore whether treatment through nume is right for you, you are welcome to start a free consultation and have one of our GPhC-registered prescribers review your case the same day.